Table 2.

Radiological and pathological tumor size of the total cohort and stratified by imaging modality and pNET localization

Overall					pNETs head				pNETs body/tail
imaging modality	N (%)	radiological size, mm	pathological size, mm	difference, mm	N (%)	radiological size, mm	pathological size, mm	difference, mm	N (%)	radiological size, mm	pathological size, mm	difference, mm
All	73 (100)	22 [3–160]	21 [4–200]	−1 [–40 to 22]	26 (35.6)	19 [3–43]	15 [4–50]	−1 [–17 to 22]	58 (79.5)	22 [5–160]	21 [4–200]	0 [–40 to 20]
MRI	36 (49.3)	23 [3–43]	21 [4–50]	−1 [–9 to 17]	14 (19.2)	16 [3–43]	14 [4–45]	−1 [–6 to 15]	29 (39.7)	21 [3–41]	20 [4–50]	0 [–15 to 17]
CT	43 (58.9)	25 [8–160]	25 [4–200]	0 [–40 to 22]	14 (19.2)	20 [7–42]	17 [4–50]	0.3 [–23 to 22]	33 (45.2)	25 [9–160]	25 [4–200]	0 [–40 to 20]
EUS	29 (39.7)	20 [6–67]	21 [4–90]	−1 [–23 to 8]	10 (13.7)	19 [5–29]	16 [5–33]	0.8 [–5 to 6]	22 (30.1)	17 [5–67]	22 [4–90]	−1 [–23 to 8]

All values are given as median [range]. The differences were calculated by subtracting the pathological size from the radiological size. CT, computed tomography; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging; N, number of; pNET, pancreatic neuroendocrine tumor.